The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Optimizing treatment of MCL
Georg Hess, MD, University Medical Center Mainz, Mainz, Germany, gives an overview of key updates in the treatment of patients with mantle cell lymphoma (MCL). Dr Hess highlights the importance of understanding how to combine therapies optimally, improving duration of response and using chimeric antigen receptor T-cell (CAR-T) therapy in suitable cohorts of patients. Dr Hess also comments on the SHINE study (NCT01776840) which is exploring the Bruton’s tyrosine kinase inhibitor ibrutinib in combination with bendamustine and rituximab in patients with newly diagnosed MCL. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
